Transarterial embolization in inflammatory arthritis: will rheumatology shape the debate or inherit it?
Abstract
The expanding use of transarterial embolization for musculoskeletal pain, most commonly operationalized as genicular artery embolization in osteoarthritis, raises a broader question that rheumatology has not yet systematically addressed: might a vessel-targeted, image-guided intervention complement pharmacological care in selected patients with inflammatory arthritis? Despite advances in treat-to-target strategies, a single persistently inflamed joint can remain the dominant source of pain and disability while composite disease activity scores indicate target achievement. When that joint is refractory and systemic escalation is either disproportionate or infeasible, the therapeutic options are narrow and poorly evidenced. This review argues that the rheumatology community should be defining where, when and for whom transarterial embolization might have a legitimate place—its positioning within the inflammatory arthritis therapeutic landscape—rather than allowing this to be shaped, by default, through fragmented case-based experience and literature centred predominantly outside the discipline. Drawing on the neurovascular biology of synovitis, the osteoarthritis evidence and emerging reports in inflammatory conditions, we map the scenarios in which the question is starting to surface and outline what a deliberate positioning effort would require. In doing so, we recognise that no prospective, randomised or disease-specific data currently support transarterial embolization in this setting and that the available signal is limited to isolated case reports. However, defining a shared language now, before uncritical diffusion occurs, is a prerequisite for responsible investigation.
Related
- Combined antegrade and retrograde transarterial approaches for embolization of a traumatic carotid‑cavernous fistula with concomitant middle meningeal arteriovenous fistula
- Unexpected para-aortic venous migration of n-butyl cyanoacrylate during transarterial sac embolization for a type II endoleak: A technical pitfall.
- Combined Transarterial Embolization and Percutaneous CT-Guided Cryoablation of Renal Cell Carcinoma: A Retrospective Single-Center Study.
- JAK Inhibitors Beyond Arthritis: Expanding Indications and Mechanisms of JAK Inhibitors in Rheumatology
- Pachydermodactyly Mimicking Inflammatory Arthritis
BibTeX
@article{ursini2026transarterial,
title = {{Transarterial embolization in inflammatory arthritis: will rheumatology shape the debate or inherit it?}},
author = {Francesco Ursini and Jacopo Ciaffi and Giancarlo Facchini and Piero Ruscitti and Roberto Caporali and Joel A Block},
journal = {Rheumatology Advances in Practice},
year = {2026},
month = oct,
doi = {10.1093/rap/rkag125},
url = {https://doi.org/10.1093/rap/rkag125},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Transarterial embolization in inflammatory arthritis: will rheumatology shape the debate or inherit it?
AU - Francesco Ursini
AU - Jacopo Ciaffi
AU - Giancarlo Facchini
AU - Piero Ruscitti
AU - Roberto Caporali
AU - Joel A Block
PY - 2026
DA - 2026/10/08
JO - Rheumatology Advances in Practice
DO - 10.1093/rap/rkag125
UR - https://doi.org/10.1093/rap/rkag125
AB - The expanding use of transarterial embolization for musculoskeletal pain, most commonly operationalized as genicular artery embolization in osteoarthritis, raises a broader question that rheumatology has not yet systematically addressed: might a vessel-targeted, image-guided intervention complement pharmacological care in selected patients with inflammatory arthritis? Despite advances in treat-to-target strategies, a single persistently inflamed joint can remain the dominant source of pain and disability while composite disease activity scores indicate target achievement. When that joint is refractory and systemic escalation is either disproportionate or infeasible, the therapeutic options are narrow and poorly evidenced. This review argues that the rheumatology community should be defining where, when and for whom transarterial embolization might have a legitimate place—its positioning within the inflammatory arthritis therapeutic landscape—rather than allowing this to be shaped, by default, through fragmented case-based experience and literature centred predominantly outside the discipline. Drawing on the neurovascular biology of synovitis, the osteoarthritis evidence and emerging reports in inflammatory conditions, we map the scenarios in which the question is starting to surface and outline what a deliberate positioning effort would require. In doing so, we recognise that no prospective, randomised or disease-specific data currently support transarterial embolization in this setting and that the available signal is limited to isolated case reports. However, defining a shared language now, before uncritical diffusion occurs, is a prerequisite for responsible investigation.
SN - 2514-1775
ER -